2025 CASH丨Dr. Rong Fu: Interpretation of the PNH China Guidelines

2025 CASH丨Dr. Rong Fu: Interpretation of the PNH China Guidelines

The 5th Annual Meeting of Chinese Alliance for Societies of Hematology (2025 CASH) was held in Tianjin from January 3 to 5, under the theme “Comprehensive Hematology, Comprehensive Health, and Comprehensive Well-being.” Top hematology experts from China and abroad were invited to discuss the latest advancements and future trends in hematology.
Annual Review | Prof. Shuhua Yi: Highlights of 2024 Advances in Mantle Cell Lymphoma

Annual Review | Prof. Shuhua Yi: Highlights of 2024 Advances in Mantle Cell Lymphoma

In recent years, the field of hematologic oncology has experienced remarkable breakthroughs, with significant advancements in mantle cell lymphoma (MCL). Chinese researchers have increasingly contributed to this progress, playing a pivotal role in driving academic development and clinical practice in the field. As we step into the new year, Hematology Frontier invited Professor Shuhua Yi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to review the major events and breakthroughs in MCL during 2024. This comprehensive summary aims to provide valuable insights for clinical practice and future research directions.
Annual Review | Dr. Liangyou Gu: Advances in Perioperative Treatment of Renal Cancer in 2024

Annual Review | Dr. Liangyou Gu: Advances in Perioperative Treatment of Renal Cancer in 2024

Renal cancer is a common malignancy of the urinary system. For localized and locally advanced renal cancer without distant or extraregional lymph node metastases, surgical removal of the tumor or the affected kidney remains the primary treatment. Recent advances in targeted therapy and immunotherapy have expanded the options for perioperative treatment of renal cancer. In 2024, this field saw significant breakthroughs, and Dr. Liangyou Gu from the Chinese PLA General Hospital shared the latest research developments.